West Australian ☀️ | Haematologist & Transplant Physician @MDAndersonNews
Houston, Texas
Joined August 2022
- Tweets60
- Following163
- Followers101
- Likes208
Happy to share our work in Leukemia, showing that donor selection (specifically DPB1 mismatching) can be harnessed to measurably reduce relapse in high risk AML/MDS patients, without effect on GVHD. nature.com/articles/s41375-0… @UTMDAnderson #bmtsm #leusm
Great to present our work from @MDAndersonNews using patient-reported outcomes to better capture the patient experience after allo-HCT. Multi-domain symptom burden can be persistent, even in those without GVHD. @ASTCT #Tandem2026 #bmtsm
Just out in @cytotherapy: MPC-based expansion and exofucosylation is safe but did not improve engraftment times. Negative studies matter too! #bmtsm
isct-cytotherapy.org/article…
Now at poster 6058 - persistent symptom burden in survivors of stem cell transplantation. despite cure; many patients have notable fatigue, sexual dysfunction and sleep disturbance - areas for future improvement! #ASH2025 #bmtsm #survivorship @MDAndersonNews
Very proud to present our work on clonal dynamics of relapse in FLT-ITD mutant AML post HCT. Three relapse archetypes emerging: FLT3 persistence, loss and ITD/TKD change - all with their own therapeutic implications. #ASH25 #amlsm #bmtsm @MDAndersonNews @sanamloghavi
Sunday 7th, Portia Smallbone presents our work on clonal dynamics of relapse in FLT3 ITD AML post HSCT, with great data on the utility of our ultra sensitive NGS for FLT3 ITD #MRD
And Monday 8th @sankalparoraMD will present our story on in frame bZIP CEBPA in ND and sAML
#ASH25
Sharing our review on SR-aGVHD: The Hope for a Better Tomorrow, just out in @AjHematology. Thank you to @WileyGlobal for the video abstract!
@MDAndersonNews #bmtsm #gvhd
onlinelibrary.wiley.com/doi/…
Excited to share @MDAndersonNews experience using maintenance decitabine/cedazuridine post-HCT. In a group of very-high risk MDS patients, dosing at days 1&3 is tolerable and efficacious with a 2-year RFS of 66.7%. @Haematologica
doi.org/10.3324/haematol.202…
Honored to present our novel regimen of fractionated busulfan, fludarabine and thiotepa conditioning for myelofibrosis at #Tandem2025, showing excellent relapse rates of 6% and PFS of 71% at 2 years. With major thanks to Samer Srour and @udaypopat @MDAndersonNews @ASTCT #bmtsm
HCT in myelofibrosis is feasible and curative in selected patients with SVT with low early mortality. However, long-term complications of portal hypertension remain an ongoing concern. #MPN #hematology #thrombosis
doi.org/10.1002/ajh.27542
2
77
Pleased to share our work recently published in @AjHematology.
In patients with MF and splanchnic vein thrombosis, HCT is feasible & curative, although long term sequelae of portal HTN require ongoing management.
#bmtsm #mpnsm @MDAndersonNews
doi.org/10.1002/ajh.27542
What an honor to discuss our poster “HLA-DPB1 mismatches and impact on unrelated donor outcomes in the PTCy era” with the queen of HLA, Katharina Fleischhauer! #ASH24 #bmtsm
In the last set of poster presentations of #ASH24 our researchers shared findings ranging from predictors of graft vs host disease to the molecular mechanisms of drug resistance in cell line models of multiple myeloma. #EndCancer
ALT Three people stand in front of a poster
ALT A woman stands in front of a poster
ALT Two people talk in front of a scientific poster
ALT A man standing in front of a scientific poster
Proud to contribute to this multi-centre study of CNS-GVHD, an area of great need of further research & standardization #bmtsm #gvhd @gvhd_hub @ASTCT
Lambert et al. describe the clinical, biological, radiological, and histopathological characteristics, as well as the course and treatment response, of a large cohort of patients with CNS involvement in graft-versus-host disease. tinyurl.com/y4nz9azt
This is so exciting! @ALLGtrials @MDAndersonNews
ALLG’s AMLM26 INTERCEPT trial has received FDA approval to open in the US at MD Anderson Cancer Center. It's the first ALLG trial open for US patients & uses molecularly targeted therapies for AML patients via an innovative, multiple adaptive arm design - allg.org.au
7
220
APOLLO: ATO+ATRA in high risk APML is safe, with superior EFS when compared to ATRA+conventional chemotherapy #EHA2024
Check out our poster @ P1364 on our experience with oral decitabine maintenance post-HCT in MDS. #EHA2024 #bmtsm @MDAndersonNews
🎓💃🏼 Thanks to all. A very special celebration @MDAndersonNews
Congratulations to the SCT Fellowship Class of ‘24 @MDAndersonNews #bmtsm #ArielFromowitz #NatalieRafaeli @PortiaSmallbone @Jeremy_Ramdial @RichardChamplin @EJShpallMD @sairah__ahmed @DQBMD @warren_fingrut @Aljawai_Y
Interesting discussion with great representation from colleagues in paediatrics and around the world! #ISCT2024
On air now @ISCTglobal #isct2024
Round table on preventing GvHD: T-cell depletion vs PtCy
Great line up; @AliceBertaina Drs Purtill, Lakkaradja, Klein, Smallbone
